Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin in Acute Heart Failure Hospitalization (China)
CTR20200939Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of empagliflozin in Acute Heart Failure (AHF), chronic heart failure (CHF), sponsored by Boehringer Ingelheim. Started Jun 2020; status: completed.
02
Drugs
empagliflozin
03
Conditions
Acute Heart Failure (AHF)chronic heart failure (CHF)
Beyond the preview
Go deeper on CTR20200939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200939.